{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:27:37Z","timestamp":1759940857613,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jinf.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T22:12:53Z","timestamp":1542060773000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fluoroquinolone use and associated adverse drug events in England"],"prefix":"10.1016","volume":"78","author":[{"given":"Larry M.","family":"Baddour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2018.11.001_bib0001","article-title":"Communicating antimicrobial resistance and stewardship in the national press: lessons from sepsis awareness campaigns","author":"Rush","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2018.11.001_bib0002","series-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","first-page":"419","article-title":"Quinolones","author":"Hooper","year":"2015"},{"key":"10.1016\/j.jinf.2018.11.001_bib0003","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/jac\/dku328","article-title":"Longitudinal trends and cross-sectional analysis of English national hospital antibacterial use over 5 years (2008\u20132013): working towards hospital prescribing quarterly measures","volume":"70","author":"Cooke","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2018.11.001_bib0004","doi-asserted-by":"crossref","first-page":"i151","DOI":"10.1093\/jac\/dks202","article-title":"Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: stay smart \u2013 then focus","volume":"67","author":"Ashiru-Oredope","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2018.11.001_bib0005","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkv095","article-title":"Time series analysis of the impact of an intervention in Tayside, Scotland to reduce primary care broad-spectrum antimicrobial use","volume":"70","author":"Hernandez-Santiago","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 6","key":"10.1016\/j.jinf.2018.11.001_bib0006","first-page":"vi3","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997\u20132009)","volume":"66","author":"Adriaenssens","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2018.11.001_bib0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40261-018-0684-7","article-title":"Indications for systemic fluoroquinolone therapy in Europe and prevalence of primary-care prescribing in France, Germany, and the UK: descriptive population-based study","volume":"38","author":"Morales","year":"2018","journal-title":"Clin Drug Investigat"},{"key":"10.1016\/j.jinf.2018.11.001_bib0008","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3201\/eid1305.061124","article-title":"Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK","volume":"13","author":"Delaney","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2018.11.001_bib0009","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.puhe.2014.06.023","article-title":"Antibacterial usage in English NHS hospitals as part of a national Antimicrobial Stewardship Programme","volume":"128","author":"Cooke","year":"2014","journal-title":"Public Health"},{"key":"10.1016\/j.jinf.2018.11.001_bib0010","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/jac\/dkt212","article-title":"Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445318303256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445318303256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:27:33Z","timestamp":1759008453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445318303256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0163445318303256"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2018.11.001","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoroquinolone use and associated adverse drug events in England","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}